Key result
LVAD implantation for destination therapy in obese patients with end-stage heart failure yielded a 1-year survival of 65%, comparable to 63% in normal-weight patients (P>0.5).
Why the study?
Does LVAD implantation for destination therapy result in similar 1-year outcomes in obese patients with end-stage heart failure compared to normal weight patients?
Population
58 consecutive patients with end-stage heart failure who are not transplant candidates, 83% men. Divided…
Comparison
Left ventricular assist device implantation for… vs Normal weight patients receiving the same LVAD…
Design
Cohort
Follow-up
1 year
Authors
Loading...
Supports LVAD destination therapy consideration in obese patients; extends observational data but leaves open need for randomized confirmation.
Cohort (n=58)
No
Does LVAD implantation for destination therapy result in similar 1-year outcomes in obese patients with end-stage heart failure compared to normal weight patients?
Absolute Event Rate: 65% vs 63%
p-value: p=>0.5
Obese patients with end-stage heart failure have similar 1-year survival and functional outcomes as normal-weight patients after LVAD implantation for destination therapy.
Coyle et al. (2009) conducted a cohort in End-stage heart failure (n=58). LVAD implantation in obese patients (BMI ≥ 30) vs. Normal weight patients (BMI ≤ 30) was evaluated on 1-year survival (p=>0.5). LVAD implantation for destination therapy in obese patients with end-stage heart failure yielded a 1-year survival of 65%, comparable to 63% in normal-weight patients (P>0.5).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: